Verve Establishes Global Collaboration with Lilly to Advance Verve’s In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease
Verve Therapeutics Verve to Receive $60 Million in Combined Upfront Payments and Equity Investments; Additional capital positioned to extend Verves’ projected liquidity trail through 2026 Verve has opt-in rights to…